A phase II study of carboplatin and vincristine in previously treated patients with small-cell lung cancer

Autor: Smit, Egbert F., Berendsen, Henk H., Vries, Elisabeth G. E., Mulder, Nanno H., Postmus, Pieter E.
Zdroj: Cancer Chemotherapy and Pharmacology; May 1989, Vol. 25 Issue: 3 p202-204, 3p
Abstrakt: A total of 28 previously treated patients with small-cell lung cancer were treated at relapse with 400 mg/m2 carboplatin and 2 mg vincristine on days 1 and 8, every 4 weeks. Ten partial responses (PRs) (37%) but no complete responses (CRs) were seen. Median survival after the start of second-line treatment was 120 days (range, 39–503 days). Toxicity of this regimen was moderate, including WHO grade 3/4 myelosuppression in 26% of courses (n=66). Eight PRs were seen in a subgroup of 22 patients who relapsed <3 months after firstline treatment. The responses seen in this group of patients may be due to the absence of cross-resistance between the regimens used.
Databáze: Supplemental Index
Externí odkaz: